BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84

* BioXcel Therapeutics press release [https://seekingalpha.com/pr/20303392-bioxcel-therapeutics-reports-third-quarter-2025-financial-results-and-provides-update-on-late] (BTAI [https://seekingalpha.com/symbol/BTAI]): Q3 GAAP EPS of -$2.18 misses by $0.84.
* Cash and cash equivalents and restricted cash totaled $37.3 million as of September 30, 2025.

MORE ON BIOXCEL THERAPEUTICS

* BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) [https://seekingalpha.com/article/4821751-bioxcel-therapeutics-inc-discuses-serenity-at-home-pivotal-phase-3-safety-trial-results-transcript]
* BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call - Slideshow [https://seekingalpha.com/article/4821752-bioxcel-therapeutics-inc-btai-special-call-slideshow]
* BioXcel regains compliance with Nasdaq listing rule [https://seekingalpha.com/news/4496013-bioxcel-regains-compliance-with-nasdaq-listing-rule]
* BioXcel whipsaws after late-stage trial win for lead asset [https://seekingalpha.com/news/4489573-bioxcel-stock-down-despite-late-stage-trial-win]
* Seeking Alpha’s Quant Rating on BioXcel Therapeutics [https://seekingalpha.com/symbol/BTAI/ratings/quant-ratings]